HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The acceptance of a 7-week cycle with a modern low-dose oral contraceptive (Minulet).

Abstract
Cycle control and tolerance were studied in a group of 55 female volunteers, who took during 42 consecutive days a modern low-dose oral contraceptive: gestodene 75 micrograms/ethinylestradiol 30 micrograms (Minulet). During these 42 days, 96% of the women experienced no breakthrough bleeding and 81% of the women experienced no spotting or breakthrough bleeding. When the findings of this study are compared with the findings of an earlier study with also a seven-week cycle but with other oral contraceptives, it can be concluded that Minulet offered an excellent cycle control.
AuthorsH Kornaat, M H Geerdink, J W Klitsie
JournalContraception (Contraception) Vol. 45 Issue 2 Pg. 119-27 (Feb 1992) ISSN: 0010-7824 [Print] United States
PMID1559335 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)
Chemical References
  • Contraceptives, Oral, Combined
  • Norpregnenes
  • Femovan
  • Ethinyl Estradiol
Topics
  • Adolescent
  • Adult
  • Contraceptives, Oral, Combined (pharmacology, standards)
  • Dose-Response Relationship, Drug
  • Ethinyl Estradiol (pharmacology, standards)
  • Female
  • Humans
  • Menstrual Cycle (drug effects)
  • Norpregnenes (pharmacology, standards)
  • Patient Compliance
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: